![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Additional information
Notes on contributors
Jan Poolman
Dr. Jan Poolman obtained a master’s degree in Chemistry in 1975 and a Ph.D. on Meningococcal Surface Structure from the University of Amsterdam (UVA), Netherlands (1976-1981, Medical Faculty). He was appointed Associate Professor of Medical Microbiology at the UVA from 1976 to 1986. In 1982 he was awarded an NIH post-doctoral fellowship research position performed at the University of Washington, Seattle, WA, USA. From 1986 until 1996, he became Head of Vaccine R&D National Public Health Institute, Bilthoven, Netherlands (RIVM). In 1997 he was appointed Head & Vice President bacterial vaccine R&D GSK Biologicals, Rixensart, Belgium. During his tenure, he contributed to the licensure of several vaccines: DTPa-HB-IPV-Hib (Infanrix-Hexa); DTPa-HB-IPV (Pediarix); Tdap (Boostrix); HibMenC-TT (Menitorix); 10-valent pneumococcal conjugate (Synflorix); HibMenCY-TT (Menhibrix), and ACWY-TT (Nimenrix). Since 2011 he has held the position of Vice President of Bacterial Vaccines at Janssen Vaccines and Prevention, Leiden, Netherlands. From 2011 to 2018 a bacterial vaccine team, laboratories and several bacterial vaccine projects including external partnerships have been built, and clinical studies have been initiated and completed with a 4-valent ExPEC vaccine (ExPEC4V). Dr. Poolman has become a global leader in the development of vaccines directed against ExPEC. In his career, Dr. Poolman has published over 200 articles in peer-reviewed publications.